Allergan has announced its acquisition of Anterios, a clinical-stage biopharmaceutical company developing a next-generation delivery system and botulinum toxin-based prescription products. Under the terms of the agreement, Allergan acquired Anterios for an up-front payment of $90 million and potential development and commercialization milestone payments related to NDS, Anterios’ proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without injection. The agreement also included global rights to ANT-1207, an investigational topical botulinum toxin type A formulation in development for the potential treatment of hyperhidrosis, acne and crow’s feet. Prior to the closing, Anterios spun out certain assets to a new company, Eirion Therapeutics, funded by Anterios shareholders. The new entity also retains certain nonexclusive rights to ANT-1207.
“This acquisition demonstrates our ability to apply our tremendous scientific leadership in neurotoxins to further extend our already deep neurotoxin pipeline by advancing a new delivery system and formulations that are appealing to both patients and physicians,” said David Nicholson, PhD, EVP and president of Global Brands Research & Development at Allergan.